Eli Lilly has been experiencing strong growth lately due to its impressive GLP-1 drugs. Eli Lilly (NYSE: LLY) has been a ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

On Tuesday, Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE: LLY) entered into a collaboration and license agreement.

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

Sarita Dhage stands out as a visionary leader and technologist in the biopharmaceutical manufacturing sector. Currently serving as Manager–MES Business Integrator at Eli Lilly and Company, she has ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

In collaboration with Eli Lilly and Company (NYSE:LLY), a pharmaceutical company recognized globally for its innovative ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

Eli Lilly and Company (NYSE:LLY) is expanding its neuroscience pipeline through the acquisition of SiteOne Therapeutics in a ...